Summary (tl;dr)

A generic version of Zyrtec, cetirizine hydrochloride 5 mg tablets, is being voluntarily recalled nationwide in the U.S. due to potential cross-contamination with ranitidine, a heartburn medication. This recall addresses concerns over possible severe allergic reactions for consumers sensitive to ranitidine.

Essential Background

Cetirizine hydrochloride is a widely used antihistamine for treating allergy symptoms, available both over-the-counter and by prescription as a generic form of Zyrtec. Ranitidine, formerly sold under the brand name Zantac, is a different class of drug used to reduce stomach acid and treat conditions like acid reflux. Ranitidine was subject to a major recall in 2020 due to contamination concerns, and a reformulated version was approved in 2025.

The Full Story

Unique Pharmaceutical Laboratories initiated a voluntary recall of four specific lots of its cetirizine hydrochloride tablets USP 5 mg (GY825029, GY825030, GY825031, GY825032) on July 18, 2026, with the U.S. Food and Drug Administration (FDA) publishing the notice on July 20, 2026. The recall stems from the discovery by a pharmacy technician of unusual red dots and discoloration on some pills during counting, indicating possible cross-contamination with ranitidine. These affected tablets were distributed nationwide across the U.S. in 100-tablet bottles by Rising Pharma Holdings Inc. No adverse events related to this recall have been reported to date.

Why It Matters

This recall is significant because individuals with a hypersensitivity to ranitidine or its ingredients could experience severe and potentially life-threatening reactions if they consume the contaminated cetirizine tablets. These adverse reactions can include anaphylaxis, low blood pressure, difficulty breathing or swallowing, swelling of the face or throat, hives, itching, or loss of consciousness. While there have been no reported incidents, the potential for serious health risks makes it crucial for consumers to check their allergy medication and consult their healthcare providers if they have any affected products.

Geographic Location

• United States (nationwide distribution and recall announcement by the FDA)
• Panoli, Gujarat, India (headquarters of the recalling manufacturer, Unique Pharmaceutical Laboratories)